In this study, we validated m909, an anti-human FRβ antibody that demonstrates in vitro efficacy via ADCC against AML cells in a dose- and expression-dependent manner for both established cell lines and primary acute myeloid leukemia cells. The gene discussed is FOLR2; the disease is acute myeloid leukemia.